SPR741 + ceftazidime

SPR741 + ceftazidime is an investigational intravenous **combination therapy** consisting of **SPR741**, a synthetic polymyxin B analog with minimal intrinsic antibacterial activity, and **ceftazidime**, a third-generation cephalosporin antibiotic. SPR741 acts by permeabilizing the outer membrane of Gram-negative bacteria, allowing greater penetration and accumulation of coadministered antibiotics such as ceftazidime. This action potentiates the activity of ceftazidime against multidrug-resistant Gram-negative pathogens, including strains otherwise resistant to ceftazidime alone. SPR741 does not have significant direct antibacterial activity but enhances the efficacy of its partner antibiotic. The combination is being developed for the treatment of serious infections caused by multidrug-resistant Gram-negative bacteria. SPR741 is being developed by Spero Therapeutics[1][2][3].